Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of BIO 300 to Reduce the Toxicity of Thoracic Radiotherapy for Patients With Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease (BREATHE)

NCT07323732 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT07323732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07323732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of BIO 300 to Reduce the Toxicity of Thoracic Radiotherapy for Patients With Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease (BREATHE)
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
January 6, 2026
Completion date
January 6, 2029
Enrollment
25 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

interstitial lung disease, interstitial lung disease due to connective tissue disease (disorder), non small cell lung cancer, non-small cell lung cancer stage i, non-small cell lung cancer stage ii, nsclc, nsclc stage ii, nsclc, stage i